The countdown is now on as we get ready to attend the European Society for Medical Oncology’s (ESMO) premier and fully onsite World Congress on Gastrointestinal Cancer (WCGIC), 29 June – 02 July, Barcelona International Convention Centre (CCIB), chaired by our Director, Josep Tabernero, alongside Founding Congress Chair, Eric Van Cutsem, University Hospital Gasthuisberg (Leuven, Belgium), and Vice Chair, Michel Ducreux, Institut Gustave Roussy (Paris, France).
The outstanding Scientific Program, devised by WCGIC 2022’s Scientific Committee comprised of several renowned leaders in GI cancer treatment, research and care, is tailored to practicing clinicians dedicated to enhancing their knowledge and advancing the treatment and management of cancers of the gastrointestinal tract.
Set to welcome an international attendance of over 3,200 delegates spanning 95 different countries, this annual gathering represents the leading global platform for the exchange and debate of the latest emerging data, new research and novel treatment approaches and trial designs in this rapidly advancing and dynamic field.
Among the leading gastroenterology, oncology, pathology, and hepatology experts, clinicians, and surgeons, as well as clinical researchers from across the globe who will be sharing pioneering research and best practices will be many VHIO Medical Oncologists and Clinical Investigators, Vall d’Hebron University Hospital (HUVH).
Reflective of their expertise and presence on the global oncology stage, not only will be they presenting latest data from various studies, selected by ESMO to first outing throughout the meeting, our researchers are also participating as invited Session Chairs, Moderators, Speakers, Discussants and Panelists.
We take this opportunity to highlight just some of their participation as follows:
- Wednesday 29 June
The BTC Patient Journey: Best Practices and Current Challenges
11:15 – 12:45h, Rooms 115-116, Level 1.
Teresa Macarulla, Principal Investigator of VHIO’s Gastrointestinal and Endocrine Tumors Group opens this first scientific session of the Congress prior to the Opening Session.
Teresa will chair and moderate invited talks, case study presentations and discussions covering patient presentation and diagnosis, biliary tract cancer subtyping and disease heterogeneity, biomarkers, key challenges and future prospects in the management of BTC, followed by a Q&A with the audience.
Welcome & Opening Session
13:00 – 13:30h, Auditorium A, Level 0.
Congress Chair and VHIO’s Director, Josep Tabernero, will be joined by Founding Congress Chair, Eric Van Cutsem, University Hospital Gasthuisberg (Leuven, Belgium), and Vice Chair, Michel Ducreux, Institut Gustave Roussy (Paris, France), to warmly welcome participants and speakers alike.
As co-Chairs of the Opening Session, they will officially kick-off the meeting with the presentation and discussion of two selected late-breaking abstracts as follows:
- LBA O-9: Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer. Speaker: TBC.
- LBA O-10: First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results. .
